Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 3
1996 3
1997 4
1998 3
1999 7
2000 13
2001 8
2002 10
2003 16
2004 19
2005 16
2006 10
2007 13
2008 14
2009 13
2010 21
2011 6
2012 8
2013 8
2014 6
2015 9
2016 10
2017 7
2018 9
2019 4
2020 8
2021 13
2022 10
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

258 results
Results by year
Filters applied: . Clear all
Page 1
Drugs for Parkinson's disease.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32. Med Lett Drugs Ther. 2021. PMID: 33647001 Review. No abstract available.
Comparison chart: Drugs for Parkinson's disease.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Dec 14;62(1613):e1-e9. Med Lett Drugs Ther. 2020. PMID: 33647002 Review. No abstract available.
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O'Brien MD, Silsbee H, Gronseth G, Lang AE; Guideline Subcommittee of the AAN. Pringsheim T, et al. Neurology. 2021 Nov 16;97(20):942-957. doi: 10.1212/WNL.0000000000012868. Neurology. 2021. PMID: 34782410 Free PMC article. Review.
The comparison of different formulations of dopamine agonists yielded little evidence that any one formulation or method of administration is superior. Long-acting forms of levodopa and levodopa with entacapone do not appear to differ in efficacy from immediate-release lev …
The comparison of different formulations of dopamine agonists yielded little evidence that any one formulation or method of administration i …
Entacapone.
Chong BS, Mersfelder TL. Chong BS, et al. Ann Pharmacother. 2000 Sep;34(9):1056-65. doi: 10.1345/aph.19328. Ann Pharmacother. 2000. PMID: 10981253 Review.
STUDY SELECTION: Relevant published human studies were chosen to summarize the pharmacokinetics, clinical efficacy, adverse effects, and drug interactions. DATA EXTRACTION: All available human clinical trials were reviewed. ...Common adverse effects in …
STUDY SELECTION: Relevant published human studies were chosen to summarize the pharmacokinetics, clinical efficacy, adverse effect …
Targeted Inhibition of FTO Demethylase Protects Mice Against LPS-Induced Septic Shock by Suppressing NLRP3 Inflammasome.
Luo J, Wang F, Sun F, Yue T, Zhou Q, Yang C, Rong S, Yang P, Xiong F, Yu Q, Zhang S, Wang CY, Li J. Luo J, et al. Front Immunol. 2021 May 4;12:663295. doi: 10.3389/fimmu.2021.663295. eCollection 2021. Front Immunol. 2021. PMID: 34017338 Free PMC article.
We herein show that nanoparticle-mediated Fto-siRNA delivery or FTO inhibitor entacapone administration dramatically inhibited macrophage activation, reduced the tissue damage and improved survival in a mouse model of LPS-induced endotoxic shock. ...
We herein show that nanoparticle-mediated Fto-siRNA delivery or FTO inhibitor entacapone administration dramatically inhibited macrop …
Entacapone.
Müller T. Müller T. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):983-93. doi: 10.1517/17425255.2010.502167. Expert Opin Drug Metab Toxicol. 2010. PMID: 20572781 Review.
The addition of the catechol-O-methyltransferase inhibitor entacapone (EN) to LD/carbidopa (CD) improves wearing off, as EN prolongs LD half-life and avoids troughs. ...
The addition of the catechol-O-methyltransferase inhibitor entacapone (EN) to LD/carbidopa (CD) improves wearing off, as EN prolongs …
COMT Inhibitors in the Management of Parkinson's Disease.
Fabbri M, Ferreira JJ, Rascol O. Fabbri M, et al. CNS Drugs. 2022 Mar;36(3):261-282. doi: 10.1007/s40263-021-00888-9. Epub 2022 Feb 25. CNS Drugs. 2022. PMID: 35217995 Review.
Currently, two peripheral COMT-Is are considered as first-line choices - entacapone (ENT), which was approved by the US Food and Drug Administration in 1999 and the European Committee in 1998; and opicapone (OPC), which was approved by the European Committee in 2016. ...Do …
Currently, two peripheral COMT-Is are considered as first-line choices - entacapone (ENT), which was approved by the US Food and Drug …
Levodopa/carbidopa/entacapone (Stalevo).
Hauser RA. Hauser RA. Neurology. 2004 Jan 13;62(1 Suppl 1):S64-71. doi: 10.1212/wnl.62.1_suppl_1.s64. Neurology. 2004. PMID: 14718682 Clinical Trial.
Most PD patients taking levodopa/carbidopa immediate-release (IR) plus entacapone can be directly switched to the corresponding dose Stalevo product. For fluctuating PD patients taking levodopa/carbidopa IR without entacapone, switching to the corresponding Stalevo …
Most PD patients taking levodopa/carbidopa immediate-release (IR) plus entacapone can be directly switched to the corresponding dose …
Entacapone/levodopa/carbidopa combination tablet: Stalevo.
[No authors listed] [No authors listed] Drugs R D. 2003;4(5):310-1. doi: 10.2165/00126839-200304050-00006. Drugs R D. 2003. PMID: 12952501 Review.
Entacapone (Comtess/Comtan) is Orion Pharma's original proprietary catechol-O-methyl transferase (COMT) inhibitor. Entacapone is able to slow down degradation of levodopa and improve the availability and efficacy of each levodopa dose, hence its use as a complement …
Entacapone (Comtess/Comtan) is Orion Pharma's original proprietary catechol-O-methyl transferase (COMT) inhibitor. Entacapone …
Entacapone - Another Parkinson's medication associated with lymphocytic colitis.
Fois AF, Conrad R, Hampe T. Fois AF, et al. Parkinsonism Relat Disord. 2021 Oct;91:83-84. doi: 10.1016/j.parkreldis.2021.09.010. Epub 2021 Sep 15. Parkinsonism Relat Disord. 2021. PMID: 34543852
In response to the report of Ong and colleagues of a series of patients with levodopa/dopa decarboxylase inhibitor associated microscopic colitis, we report a case of entacapone associated microscopic colitis. We agree that chronic diarrhoea in patients with Parkinson's di …
In response to the report of Ong and colleagues of a series of patients with levodopa/dopa decarboxylase inhibitor associated microscopic co …
258 results